After a recent scan, we can see that American Renal Associates Holdings, Inc. (NYSE:ARA) has a Shareholder Yield of -0.037782 and a Shareholder Yield (Mebane Faber) of -0.01711. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. As the markets continue to charge to new heights, investors may be trying to calculate where the markets will be moving in the next few months. Many market enthusiasts will be monitoring the current round of company earnings reports. A better than expected earnings period may help give the stock market another boost to even greater levels. At this point in time, investors may be a bit more cautious with stock selection. With so many names near all-time highs, investors may need to crunch the numbers to evaluate which stocks are still a good buy even at current price levels. Investors may also want to zoom out to the sector level and see if they can determine which sectors may be poised to outperform the overall market coming in to the second part of the year. Investors may also be looking at the overall economic conditions and striving to gain a sense of whether everything will align to keeping the bull run going. 

Valuation Scores
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of American Renal Associates Holdings, Inc. (NYSE:ARA) is 4.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.  The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.  The ERP5 of American Renal Associates Holdings, Inc. (NYSE:ARA) is 4064.  The lower the ERP5 rank, the more undervalued a company is thought to be. The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price.  The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.  The MF Rank of American Renal Associates Holdings, Inc. (NYSE:ARA) is 866.  A company with a low rank is considered a good company to invest in.  The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

The Q.i. Value of American Renal Associates Holdings, Inc. (NYSE:ARA) is 10.00000.  The Q.i. Value is a helpful tool in determining if a company is undervalued or not.  The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity.  The lower the Q.i. value, the more undervalued the company is thought to be.

The Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of American Renal Associates Holdings, Inc. (NYSE:ARA) is 39.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings.  Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.  The Value Composite Two of American Renal Associates Holdings, Inc. (NYSE:ARA) is 48.

American Renal Associates Holdings, Inc. (NYSE:ARA) has a Price to Book ratio of -5.452752. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of 3.485000, and a current Price to Earnings ratio of -25.617239. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow.  The FCF Growth of American Renal Associates Holdings, Inc. (NYSE:ARA) is -0.387626.  Free cash flow (FCF) is the cash produced by the company minus capital expenditure.  This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends.  The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.  The FCF Score of American Renal Associates Holdings, Inc. (NYSE:ARA) is 0.386129.  Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years.  The score is a number between one and one hundred (1 being best and 100 being the worst).  The Gross Margin Score of American Renal Associates Holdings, Inc. (NYSE:ARA) is 10.00000.  The more stable the company, the lower the score.  If a company is less stable over the course of time, they will have a higher score.

Price Index
The Price Index is a ratio that indicates the return of a share price over a past period. The price index of American Renal Associates Holdings, Inc. (NYSE:ARA) for last month was 1.08348. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for American Renal Associates Holdings, Inc. (NYSE:ARA) is 0.67747. Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks.  The Price Range of American Renal Associates Holdings, Inc. (NYSE:ARA) over the past 52 weeks is 0.524000.  The 52-week range can be found in the stock’s quote summary.

Ever wonder how investors predict positive share price momentum?  The Cross SMA 50/200, also known as the “Golden Cross” is the fifty day moving average divided by the two hundred day moving average.  The SMA 50/200 for American Renal Associates Holdings, Inc. (NYSE:ARA) is currently 0.73638.  If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average – indicating a positive share price momentum.  If the Golden Cross is less than 1, then the 50 day moving average is below the 200 day moving average, indicating that the price might drop.

There are many factors that can affect the health of a certain company. Because of this, it can be extremely difficult to find one single strategy that will prove successful in the stock market. Investors are able to study all the different data, but figuring out the relevant information can be a struggle. There is plenty of company information that can easily be measured such as revenue and profits. There are also elements that aren’t as easily computed such as reputation and competitive advantage. Finding a way to gather all the information and craft a strategy that incorporates all aspects of a company may be a challenge for investors. Because there is a highly inherent human element to picking stocks, price action may not follow expectations. Human emotion can reverse course rapidly over a short period of time. Investors need to always be prepared for market uncertainty while attempting to keep emotions in check. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.